David Lewis

Dr. Lewis has over 15 years of leadership experience in the biotechnology industry. He was a pioneer in the use of RNAi in insects and was the first to show that siRNAs could be used to inhibit gene expression in multiple tissues of adult mammals. Dr. Lewis began his career at MirusBio where he spearheaded the effort to develop RNAi-based therapeutics. After acquisition of MirusBio by Roche, he held positions of increasing responsibility within Roche’s RNA Therapeutics division rising to the rank of Director of Research and Site Head of Roche Madison. Dr. Lewis was most recently Chief Scientific Officer at Arrowhead Pharmaceuticals where he oversaw Arrowhead’s pre-clinical research and drug development programs. Dr. Lewis received a Bachelor’s degree in Biochemistry and Molecular Biology from the University of Wisconsin and a Ph.D. in Biochemistry from Michigan State University. His post-doctoral studies were performed at the Howard Hughes Medical Institute at the University of Wisconsin. He is a named inventor on over 50 patents and has over 30 publications and book chapters. Dr. Lewis has held an Adjunct Professor position at the University of Wisconsin since 2015.